scholarly journals Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan

2021 ◽  
Vol Volume 17 ◽  
pp. 3781-3790
Author(s):  
Takeshi Inoue ◽  
Shinji Fujimoto ◽  
Tatsuro Marumoto ◽  
Tadayuki Kitagawa ◽  
Kazuyuki Ishida ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Therapeutic Potential ◽  
Anxious Depression ◽  
Post Hoc Analysis ◽  
Post Hoc

Effects of Low-Volume, High-Intensity Interval Training Compared with Continuous Training on Regional and Global Body Composition in Adults with Metabolic Syndrome: A post hoc Analysis of a Randomized Clinical Trial

2021 ◽  
pp. 1-10
Author(s):  
Juan Carlos Aristizabal ◽  
Esperanza Montoya ◽  
Yeliana L. Sánchez ◽  
Manuela Yepes-Calderón ◽  
Raul Narvaez-Sanchez ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Body Composition ◽  
Interval Training ◽  
High Intensity Interval Training ◽  
Continuous Training ◽  
Post Hoc Analysis ◽  
Low Volume ◽  
High Intensity Interval ◽  
Post Hoc

Objective: The aim of this study was to compare the effects of low-volume, high-intensity interval training (HIIT) or moderate-intensity continuous training (MICT) on body composition in adults with metabolic syndrome (MS). Methods: This is a post hoc analysis of the randomized clinical trial Intraining-MET. Sixty adults (40–60 years old) were randomized to an MICT (n = 31) or HIIT (n = 29) supervised programme 3 days/week for 12 weeks. MICT sessions were conducted for 36 min at 60% of peak oxygen consumption (VO2peak). HIIT sessions included 6 intervals at 90% VO2peak for 1 min, followed by 2 min at 50% VO2peak. Body composition was assessed with dual energy X-ray absorptiometry. Results: Body weight did not change from pre- to post-training in either MICT (78.9 ± 15.6 kg; 77.7 ± 16.5 kg, p = 0.280) or HIIT groups (76.3 ± 13.4 kg; 76.3 ± 13.7 kg, p = 0.964). Body fat percentage and fat mass (FM) decreased post-training in the MICT (−0.9%; 95% confidence interval [CI]: −0.27 to −1.47 and −0.7 kg; 95% CI: −0.12 to −1.30) and HIIT groups (−1.0%; 95% CI: −0.32 to −1.68 and −0.8 kg; 95% CI: −0.17 to −1.47). Compared to the HIIT programme, MICT significantly reduced android FM (−0.14 kg; 95% CI: −0.02 to −0.26). Lean mass (LM) increased post-training in MICT (+0.7 kg; 95% CI: 0.01–1.41) and HIIT groups (+0.9 kg; 95% CI: 0.12–1.64), but only HIIT increased the trunk LM (+0.6 kg; 95% CI: 0.06–1.20). Conclusions: Both MICT and HIIT reduced FM without changing body weight in adults with MS. MICT had additional benefits by reducing the android FM, whereas HIIT seemed to increase LM. Given the characteristics of the post hoc analysis, further research is required to confirm these results.

Hydromorphone extended release for neuropathic and non-neuropathic/nociceptive chronic low back pain: A post hoc analysis of data from a randomized, multicenter, double-blind, placebo-controlled clinical trial

2014 ◽  
Vol 10 (5) ◽  
pp. 311 ◽  
Author(s):  
Srinivas Nalamachu, MD ◽  
Martin Hale, MD ◽  
Arif Khan, MD
Keyword(s):  
Clinical Trial ◽  
Low Back Pain ◽  
Extended Release ◽  
Controlled Clinical Trial ◽  
Low Back ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Post Hoc Analysis ◽  
Titration Phase ◽  
Post Hoc

Objective: The aim of this study was to determine the efficacy and tolerability of hydromorphone extended release (ER) in patients with chronic low back pain (LBP) with or without a neuropathic component.Design: This was a post hoc analysis of data from a multicenter, double-blind, placebo-controlled clinical trial using a randomized withdrawal design, performed in patients with moderate to severe chronic LBP. Patients achieving stable doses of hydromorphone ER during a 2- to 4-week conversion and titration phase were randomized to continue treatment with hydromorphone ER or taper-down to placebo during a 12-week double-blind phase. The primary efficacy outcome was the mean change in 11-point Numeric Rating Scale (NRS) pain intensity score from randomization to the final visit of the double-blind phase. Tolerability was assessed by recording adverse events (AEs). Data were analyzed separately for patients with non-neuropathic and neuropathic LBP.Results: A total of 173 patients with non-neuropathic/nociceptive LBP and 94 with neuropathic LBP were randomized into the double-blind phase. During the conversion and titration phase, mean (SD) NRS scores decreased significantly from 6.5 (1.87) and 6.4 (1.99) at screening to 3.3 (0.98) and 3.2 (1.05), respectively. For both LBP subgroups, patients randomized to hydromorphone ER maintained this improvement over the double-blind treatment period, whereas those randomized to placebo reported significant increase in NRS scores. Across subgroups, the incidence of 1 or more AE was 54 percent to 57 percent in the conversion and titration phase and 47 percent to 55 percent in the double-blind phase.Conclusions: The results of this study indicate that hydromorphone ER is efficacious and generally well tolerated in the management of patients with non-neuropathic and neuropathic chronic LBP.

Sign in / Sign up

Export Citation Format

Share Document